Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
Raja Bobba1, Jonathan D Adachi21Department of Medicine, St. Joseph’s Healthcare - McMaster University, 2Department of Medicine, Alliance for Better Bone Health Chair in Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, ON, CanadaAbstract: Osteoporosis in men i...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2007
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b45567b05e58473f8e6434d1cd6ff6ca |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Raja Bobba1, Jonathan D Adachi21Department of Medicine, St. Joseph’s Healthcare - McMaster University, 2Department of Medicine, Alliance for Better Bone Health Chair in Rheumatology, St. Joseph’s Healthcare, McMaster University, Hamilton, ON, CanadaAbstract: Osteoporosis in men is an increasingly recognized problem with associated fracture morbidity and mortality. Treatment is limited, with the bisphosphonates being the mainstay of therapy. Risedronate has demonstrated fracture efficacy in women and efficacy has been recently been investigated in men. In men, risedronate either maintains or increases bone mineral density. In placebo controlled trials it has been shown to be safe and effective in preventing fractures.Keywords: male osteoporosis, risedronate, bone mineral density, fractures |
|---|